Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL4I1 | Q96RQ9 | 7/20 | 0.79 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 6/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30948059 | 0.98 | IL4I1 (0.76) | IL4I1EPHX2PDE4AMAPTSMN1; SMN2 | |
| SCHEMBL30948292 | 0.89 | IL4I1 (0.80) | IL4I1EPHX2MAPTSMN1; SMN2RXFP1 | |
| SCHEMBL27163698 | 0.89 | IL4I1 (1.00) | IL4I1MAPTSMN1; SMN2RXFP1 | |
| SCHEMBL30948240 | 0.87 | IL4I1 (0.77) | IL4I1EPHX2MAPTSMN1; SMN2RXFP1 | |
| SCHEMBL30947922 | 0.86 | IL4I1 (0.96) | IL4I1MAPTSMN1; SMN2RXFP1 | |
| SCHEMBL30948026 | 0.84 | IL4I1 (0.76) | IL4I1MAPTSMN1; SMN2RXFP1TP53 | |
| SCHEMBL30948277 | 0.82 | IL4I1 (0.72) | IL4I1MAPTSMN1; SMN2RXFP1TP53 | |
| SCHEMBL30948266 | 0.81 | IL4I1 (1.00) | IL4I1PDE4ARXFP1TP53KCNH2 | |
| SCHEMBL30948042 | 0.79 | IL4I1 (0.50) | IL4I1EPHX2MAPTSMN1; SMN2KCNH2 | |
| SCHEMBL30947977 | 0.79 | IL4I1 (0.96) | IL4I1PDE4ARXFP1TP53KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL2 | IL4I1 1/4885EPHX2 3776/4885PDE4A 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.